Last updated: June 26, 2026
Amgen Inc. v. F. Hoffmann-LaRoche Ltd (case no. 1:05-cv-12237) is a federal patent litigation matter. A litigation summary and patent-strength analysis requires the specific asserted patents, claims, procedural history, claim construction outcomes, and final disposition (judgment, settlement, or dismissal). Those case-docket specifics are not provided in the prompt, and no reliable litigation record can be produced from the case caption alone.
What patents were asserted in Amgen Inc. v. F. Hoffmann-LaRoche Ltd (1:05-cv-12237)?
No asserted-patent list is provided. A compliant litigation analysis cannot be generated without identifying the patent numbers, inventors, assignees, expiration dates, and the asserted claim sets.
Which Amgen patents did Roche allegedly infringe?
Not specified.
What Roche products and acts of infringement were alleged?
Not specified.
What claim terms were construed and what were the outcomes?
Not specified.
What happened procedurally in the Amgen v. Roche case (1:05-cv-12237)?
No procedural milestones are provided (responsive pleadings, Markman schedule, summary judgment motions, Daubert rulings, trial dates, or appellate steps).
Was there a Markman hearing or summary judgment?
Not specified.
Did the case reach trial?
Not specified.
Were there appeals from a final judgment?
Not specified.
How did the court rule on infringement and validity in Amgen v. Roche?
A validity and infringement analysis requires the court’s holdings, such as infringement findings by claim, enablement, written description, indefiniteness, obviousness, and anticipation findings, plus any § 101 subject-matter outcomes.
What was the final disposition?
Not specified.
Were any patents found invalid or not infringed?
Not specified.
Did Amgen and Roche settle the litigation in 1:05-cv-12237, and what were the terms?
Settlement analysis requires the existence of a settlement agreement and its terms, including any license, covenant-not-to-sue scope, payment or royalty structure, “carve-outs” by indication or formulation, and confidentiality boundaries.
Not specified.
What Paragraph IV or FDA-related issues overlapped with Amgen v. Roche (1:05-cv-12237)?
Linking a patent suit to FDA exclusivity or regulatory milestones requires the specific FDA action and Orange Book/BLA reference points, as well as any contemporaneous ANDA/BLA filings that triggered the case.
Not specified.
How strong was Amgen’s patent estate versus Roche’s defenses in the litigation?
A “strength” analysis requires the asserted patents and the court’s invalidity and infringement rulings, including which specific defenses succeeded.
Not specified.
Which jurisdictions and courts handled key phases of Amgen v. Roche?
The prompt provides only a case number and caption. A jurisdictional map requires at least: district, assignment, presiding judge, venue changes, and any related consolidated actions.
Not specified.
What is the commercial impact of Amgen v. Roche (1:05-cv-12237)?
Commercial impact analysis depends on the product tied to the asserted patents, the revenue exposure, launch timing, generic or biosimilar impact, and licensing implications created by the outcome.
Not specified.
How does Amgen v. Roche (1:05-cv-12237) compare with related Amgen v. Roche patent disputes?
Comparison requires the related case list: other docket numbers, asserted patent families, outcomes, settlement terms, and time correlations.
Not specified.
Key Takeaways
- The case caption and docket number alone are insufficient to produce a complete litigation summary that meets patent-analyst standards.
- A credible analysis requires the asserted-patent set, procedural history, court rulings, and final disposition for 1:05-cv-12237.
- No infringement, validity, settlement, or regulatory overlap conclusions can be stated without the underlying docket record.
FAQs
-
What patents were asserted in 1:05-cv-12237 Amgen v. Roche?
Not provided.
-
Did 1:05-cv-12237 involve a Markman claim construction and what did the court construe?
Not provided.
-
What was the final outcome of Amgen Inc. v. Roche (1:05-cv-12237)?
Not provided.
-
Were there any settlement agreements or licenses tied to 1:05-cv-12237?
Not provided.
-
Did the case affect FDA exclusivity, ANDA, or biosimilar entry plans?
Not provided.
References
- U.S. District Court docket, Amgen Inc. v. F. Hoffmann-LaRoche Ltd., No. 1:05-cv-12237.
